Implementation of diagnostic screening for congenital heart disease in Hidalgo, Mexico

Atitlán-Gil, Alfonso; Mendiola-Figueroa, Luciano R; Morales-Argüelles, Víctor H; Salomón-Ganado, Arturo; Medécigo-Castelán, Enrique; Erdmenger-Orellana, Julio

doi:10.24875/acme.m20000084

Cited by 4 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La evidencia encontrada sugiere que la oximetría de pulso, además del examen físico neonatal, presenta características operativas óptimas que la convierten en una prueba de tamizaje adecuada para la detección de CCHD en recién nacidos, fundamental en entornos de bajos y medianos recursos donde el apoyo tecnológico no está totalmente disponible 63 . Esta prueba es factible y conveniente, ya que agiliza el traslado del recién nacido a hospitales de tercer nivel, lo cual reduce la estancia hospitalaria y los costos de atención 64 .…”

Section: S(1) 15unclassified

Consenso formal basado en la evidencia y opinión de expertos en inmunoprofilaxis con palivizumab en pacientes con cardiopatía congénita

2024

RCCAR

View full text Add to dashboard Cite

show abstract

Section: S(1) 15unclassified

Consenso formal basado en la evidencia y opinión de expertos en inmunoprofilaxis con palivizumab en pacientes con cardiopatía congénita

2024

RCCAR

View full text Add to dashboard Cite

show abstract

“…80 En el año 2014 se realizó el proyecto de decreto único para reformar el Artículo 60 de la Ley General de Salud para el Estado de Baja California Sur, donde se incluye de forma obligatoria el tamizaje cardioló-www.medigraphic.org.mx gico neonatal; la reforma fue publicada en el Boletín Oficial del Gobierno del Estado de Baja California Sur el 1° de septiembre de 2015, siendo el primer estado de la república en establecer el tamiz cardiaco de forma obligatoria con base en la legislación local, 81,82 seguido del estado de Sonora, el cual estableció su obligatoriedad con base en la reforma a la fracción II del artículo 50 de la Ley de Salud para el Estado de Sonora, publicado en el Boletín Oficial del Gobierno del Estado en mayo de 2017, donde además desde el año 2016 se han tamizado 22,000 RN. 83 Actualmente existen en Sonora cinco hospitales donde se realiza de forma permanente el TNC.…”

Section: Acciones Nacionales Para La Implementación Del Tncunclassified

Tamiz neonatal cardiaco: beneficios de su implementación en México

2022

Revista Mexicana De Pediatría

View full text Add to dashboard Cite

The neonatal cardiac screen is a simple, non-invasive, painless and cost-effective test, with which critical congenital heart disease can be detected in a timely manner. Diseases that can cause serious sequelae or death of newborns, if not diagnosed in time. These malformations require some type of invasive procedure during the first month of life. According to the algorithms published as of 2011, it is performed by measuring pulse oximetry in the right hand and either of the two feet of neonates, with sequential measurements and established cut-off points. In Mexico, in compliance with national and international regulations, the screening has been implemented in some States of the Republic, with its addition as a screening test in the general health law in 2021, which makes it a mandatory study in the Mexican territory. In this document, global background, scientific, technical, operational, regulatory and economic aspects for the proper performance of screening are exposed, also proposing modifications to the algorithm and making known the analysis carried out on the costs and benefits of the Neonatal Cardiac Screen. The objective of making adjustments to the algorithm is to adapt to the demographic conditions of the Mexican population, in such a way that the number of false positives and false negatives related to geographic altitude and the measurement of the perfusion index can be reduced.

show abstract

“…It is estimated that 12,000 to 16,000 newborns have CHD each year. Several very recent publications exist on POS [ 32 , 33 , 34 ] and according to the report of the National Institute of Statistics and Geography (INEGI) [ 35 ], CHD represents the second leading cause of death in children under 5 years of age.…”

Section: Cchd Screening Implementation Efforts In Latin American Cmentioning

confidence: 99%

CCHD Screening Implementation Efforts in Latin American Countries by the Ibero American Society of Neonatology (SIBEN)

Sola

Rodríguez

Young

et al. 2020

IJNS

View full text Add to dashboard Cite

Congenital heart disease (CHD) is among the four most common causes of infant mortality in Latin America. Pulse oximetry screening (POS) is useful for early diagnosis and improved outcomes of critical CHD. Here, we describe POS implementation efforts in Latin American countries guided and/or coordinated by the Ibero American Society of Neonatology (SIBEN), as well as the unique challenges that are faced for universal implementation. SIBEN collaborates to improve the neonatal quality of care and outcomes. A few years ago, a Clinical Consensus on POS was finalized. Since then, we have participated in 12 Latin American countries to educate neonatal nurses and neonatologists on POS and to help with its implementation. The findings reveal that despite wide disparities in care that exist between and within countries, and the difficulties and challenges in implementing POS, significant progress has been made. We conclude that universal POS is not easy to implement in Latin America but, when executed, has not only been of significant value for babies with CHD, but also for many with other hypoxemic conditions. The successful and universal implementation of POS in the future is essential for reducing the mortality associated with CHD and other hypoxemic conditions and will ultimately lead to the survival of many more Latin American babies. POS saves newborns’ lives in Latin America.

show abstract

Implementation of diagnostic screening for congenital heart disease in Hidalgo, Mexico

Cited by 4 publications

References 13 publications

Consenso formal basado en la evidencia y opinión de expertos en inmunoprofilaxis con palivizumab en pacientes con cardiopatía congénita

Consenso formal basado en la evidencia y opinión de expertos en inmunoprofilaxis con palivizumab en pacientes con cardiopatía congénita

Tamiz neonatal cardiaco: beneficios de su implementación en México

CCHD Screening Implementation Efforts in Latin American Countries by the Ibero American Society of Neonatology (SIBEN)

Contact Info

Product

Resources

About